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Abstract Bisphosphonates (BPs) slow bone loss by 
reducing initiation of new basic multicellular units (BMUs). 
Whether or not BPs simply prevent osteoclasts from initi­
ating new BMUs that resorb bone or also reduce the amount 
of bone they resorb at the BMU level is not clear. The goal of 
this study was to determine the effects of BPs on three 
morphological parameters of individual BMUs, resorption 
depth (Rs.De), area (Rs.Ar), and width (Rs.Wi). After 1 year 
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of treatment with vehicle (VEH), alendronate (ALN; 0.10, 
0.20, or 1.00 mg/kg/day), or risedronate (RIS; 0.05, 0.10, or 
0.50 mg/kg/day), resorption cavity morphology was asses­
sed in vertebral trabecular bone of beagle dogs by histology. 
Animals treated with ALN or RIS at the doses representing 
those used to treat postmenopausal osteoporosis (0.20 and 
0.10 mg/kg/day, respectively) had signiﬁcantly lower Rs.Ar 
(-27%) and Rs.Wi (-17%), with no difference in Rs.De, 
compared to VEH-treated controls. Low doses of ALN and 
RIS did not affect any parameters, whereas higher doses 
resulted in similar changes to those of the clinical dose. There 
were no signiﬁcant differences in the resorption cavity 
measures between RIS and ALN at any of the dose equiva­
lents. These results highlight the importance of examining 
parameters beyond erosion depth for assessment of resorp­
tion parameters. Furthermore, these results suggest that in 
addition to the well-known effects of BPs on reducing the 
number of active BMUs, these drugs also reduce the activity 
of osteoclasts at the individual BMU level at doses at and 
above those used clinically for the treatment of postmeno­
pausal osteoporosis. 
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Bisphosphonates (BPs) are commonly used to prevent or 
treat osteoporosis and other metabolic or oncogenic dis­
eases that result in increased bone remodeling [1]. BPs act 
by preventing osteoclast activation and causing apoptosis of 
osteoclasts, resulting in the initiation of fewer active basic 
multicellular units (BMUs) on bone surfaces [2]. Whether 
or not BPs affect osteoclast activity at the individual BMU 
level, i.e., the amount of bone that a team of osteoclasts 
resorbs, is less clear. Suppressing osteoclast resorption at 
the BMU level would represent an additional means 
through which these drugs slow the rate of bone loss. 
BMUs occur in vivo as three-dimensional units, yet they 
are most often assessed in the laboratory as two-dimensional 
structures via histomorphometry. Numerous techniques 
have been used to assess morphological properties of the 
BMU, and although the speciﬁc methods can differ, they all 
focus on reconstructing BMUs in order to estimate various 
parameters [3–6]. The most common parameter used to 
determine BMU-level resorption activity is resorption depth 
(Rs.De), deﬁned as the maximum distance from the cement 
line of a BMU to the estimated original trabecular surface. In 
a balanced remodeling system, this would be the same as 
ﬁnal wall width, but when resorption and formation are not 
balanced, wall width could be either greater or less than the 
Rs.De. Studies examining BP treatment effects on Rs.De 
have been equivocal, with most showing no difference 
compared to untreated controls [3, 5, 7–9]. 
The goal of the current study was to determine the 
effects of BPs on BMU-level bone resorption measures 
beyond those of Rs.De. Speciﬁcally, we examined how 
BPs affect resorption space area (Rs.Ar) and resorption 
space width (Rs.Wi), along with the more commonly 
assessed Rs.De. We hypothesized that BMU Rs.Ar would 
be lower in animals treated with BPs compared to controls 
as a result of lower Rs.De and Rs.Wi. 
Methods 
Detailed methods concerning this experiment have been 
previously published [10], and all procedures related to this 
work were approved by the Indiana University School of 
Medicine Institutional Animal Care and Use Committee 
before the study initiation. Brieﬂy, 84 skeletally mature 
female beagles were treated for 1 year with vehicle (VEH), 
alendronate (ALN; 0.10, 0.20, or 1.00 mg/kg/day), or 
risedronate (RIS; 0.05, 0.10, or 0.50 mg/kg/day). The 
middle dose for each drug corresponds, on a mg/kg basis, 
to the treatment dose for postmenopausal osteoporosis. 
Before necropsy, most animals were injected with calcein 
using a 2–12–2–5 labeling schedule; some animals (n = 3 
per group) were labeled using a 2–5–2–5 schedule. The 
shorter interlabel duration was due to a scheduling error. 
Second lumbar vertebrae were embedded, undecalciﬁed, in 
plastic, and 8-lm-thick unstained midsagittal sections were 
prepared [10]. 
Sections were inspected, blinded to treatment, at 9250 
magniﬁcation with an Olympus BH-2 microscope under 
both ultraviolet and polarized light to view the calcein labels 
and lamellae, respectively. For each animal, resorption 
cavities were identiﬁed for analysis using the following 
criteria: (1) resorption cavities that resided on a ﬂat, con­
tinuous trabecular surface, (2) double calcein labels dis­
played characteristic bow shaped curves meeting at the ends 
Fig. 1 Photomicrographs of a typical basic multicellular unit (BMU) 
for which analysis of resorption parameters was conducted. a BMU 
viewed with epiﬂuorescence to identify calcein labeling which 
indicates active bone remodeling. b BMU viewed with polarized 
light to identify the cement line which indicates the limit to erosion of 
the remodeling unit. c Overlay of the two images used for 
measurement of BMU morphology along with lines depicting how 
the surface of the cavity was estimated for assessment of resorption 
cavity width (Rs.Wi) and depth (Rs.De). Resorption cavity area 
(Rs.Ar) was deﬁned as the space within the entire cavity, Images are 
shown at original magniﬁcation 9250 
(Fig. 1a), and (3) lamellae were clear and followed the same 
contour as the calcein labels (Fig. 1b). Our choice to restrict 
our analysis to ﬂat surfaces was to eliminate the likely var­
iability associated with estimating the projected bone sur­
face on BMUs located on curves. After identiﬁcation of 
BMUs ﬁtting the above criteria, both ultraviolet and polar­
ized light images of the region were taken by a PaxCam 
camera (MIS Inc.). 
Rs.Ar, Rs.Wi, and Rs.De were measured by ImageJ 
software (NIH) with the calcein and ultraviolet light ima­
ges overlaid (Fig. 1c). All measures were made by a single 
observer who was blinded to the treatment. The perimeter 
of the resorption cavity was outlined by using the end­
points, determined by the lamellar contour and the points 
where the double calcein labels joined, and the deepest 
lamellae that followed the contour of the calcein label. 
Rs.Ar was deﬁned as the space within the perimeter, Rs.Wi 
as the distance between the endpoints, and Rs.De as the 
largest distance at a 90-degree angle from the projected 
bone surface to the cement line of the resorption cavity. 
This Rs.De constituted the maximum ﬁnal depth of the 
individual cavity (Fig. 1c). For each animal, between three 
and ﬁve individual sites were analyzed. Parameters from 
the multiple resorption cavities were averaged to obtain a 
single value for each animal. 
Variables were compared across groups by a one-way 
analysis of variance (ANOVA) with signiﬁcance deﬁned as 
P \ 0.05. Separate one-way ANOVAs were run for 
VEH ? ALN groups and VEH ? RIS groups. When 
ANOVA indicated signiﬁcant differences, post hoc analy­
sis was performed by Fisher’s protected least signiﬁcant 
difference (PLSD) test. Unpaired t-tests were used to assess 
differences in the dose equivalents of RIS and ALN. All 
data are presented as mean ± standard error. 
Results 
Treatment with ALN or RIS at doses consistent with those 
used for treatment of postmenopausal osteoporosis signif­
icantly reduced Rs.Ar by -31% (ALN) and -26% (RIS) 
compared to VEH-treated animals (Fig. 2a). These doses 
also signiﬁcantly reduced Rs.Wi (Fig. 2c) by -25% (ALN) 
and -14% (RIS), but had no signiﬁcant effect on resorp­
tion cavity depth: -14% (ALN) and -13% (RIS) com­
pared to VEH-treated animals (Fig. 2b). There was no 
signiﬁcant difference between dose equivalents of RIS and 
ALN for any resorption cavity parameters. 
At lower doses, neither RIS nor ALN signiﬁcantly 
altered any parameter of BMU morphology. The highest 
doses of both RIS and ALN produced changes in BMU 
morphology similar to those of the osteoporosis-relevant 
middle doses. 
Fig. 2 Basic multicellular unit resorption parameters. a Resorption 
area, b depth, and c width. Differences among groups were assessed 
separately for control and alendronate groups and for control and 
risedronate groups with post hoc tests within those groups when 
appropriate (overall P \ 0.05). Data presented as mean ± standard 
errors from 8–12 animals per group. P \ 0.05 vs. control (*) and low 
dose within treatment (#). No differences were found between RIS 
and ALN at equivalent doses, nor between the middle and high dose 
within treatment groups 
Discussion 
BPs are widely used to treat metabolic bone diseases, the 
most prominent of which is postmenopausal osteoporosis. 
BPs exert their positive effects on the skeleton by sup­
pressing the amount of bone remodeling [1, 2]. Clinically, 
this remodeling suppression is assessed by serum/urine 
biomarkers of collagen breakdown and in some cases 
through the assessment of bone biopsy samples by histol­
ogy. In histological analysis, the most prominent effect of 
BPs is that they reduce the number of active BMUs. In 
untreated individuals, there tends to be an imbalance 
between resorption and formation in each BMU, such that 
each BMU tends to have a net negative bone balance (less 
bone is formed than is removed) [11, 12]. This, combined 
with the more transient effect of the greater number of 
resorption sites produced as a consequence of increased 
activation frequency, leads to signiﬁcant bone loss in 
osteoporosis. By lowering the number of active BMUs with 
BP treatment, bone loss is slowed. 
It has been suggested that in addition to reducing the 
number of active BMUs, BPs affect the individual activity 
of osteoclasts within a BMU. Speciﬁcally, studies have 
assessed erosion depth, measured as the distance from the 
cement line to the bone surface (or estimated bone surface) 
of an individual BMU, which is indicative of osteoclast 
activity within a given remodeling site. The results from 
these analyses are equivocal, showing a tendency for BP 
treatment to reduce Rs.De, but rarely reaching statistical 
signiﬁcance [3, 5, 7–9, 13]. In the current study, we have 
expanded the morphological assessment of individual 
BMUs to include both Rs.Ar and Rs.Wi, in addition to the 
more traditional measure of Rs.De. We show that BPs, at 
doses equal to and above those used to treat postmeno­
pausal osteoporosis result in smaller Rs.Ar and Rs.Wi of 
individual BMUs with a nonsigniﬁcant trend toward lower 
Rs.De. These results provide evidence that in addition to 
the effect of suppressing the number of remodeling units, 
BPs also reduce the amount of bone resorbed within each 
BMU. Because Rs.De is not signiﬁcantly reduced, this is 
likely caused not by the reduction in individual activity of 
an osteoclast, but by fewer osteoclasts (perhaps due to 
increased apoptosis) working within an individual BMU. 
The implications of these data are signiﬁcant in that they 
provide evidence of a second tissue-level mechanism— 
reduced BMU resorption size—for reduced bone loss with 
BPs. Of course, this would depend on formation at the 
individual BMU level being unaffected with BPs. We have 
previously shown, in these same specimens, that wall width 
(a measure of osteoblast reﬁlling of remodeling sites) was 
not altered by BPs [10]. 
Previous analyses on these same vertebrae have also 
shown that these BP doses signiﬁcantly suppressed acti­
vation frequency, the rate of new BMU initiation [10], and 
that the effects were dose-dependent with RIS. In the 
current work, we show that only the two higher doses of 
each agent signiﬁcantly reduced BMU-level resorption 
activity, with no difference between the two higher doses 
of RIS. This leads us to speculate that these two effects of 
BPs, suppression of the number of BMUs and osteoclast 
activity within the BMU, are controlled independent of one 
another, at least for RIS. 
Several methods have been used to assess resorption 
cavities morphology [3–6]. These techniques, which were 
used on human biopsy and animal samples, are similar to 
the current work in that the BMU is reconstructed by 
making various assumptions about where the initial bone 
surface was before resorption. One different aspect of the 
current work is that we restricted our analysis to those 
surfaces that were actively forming at the time of sacriﬁce 
(deﬁned by the presence of calcein label). This was done 
in order to assure that the BMUs we measured in the 
treated animals were in fact active during the period of 
treatment. If nonlabeled cavities were assessed, it would 
not be possible to know that the BMU was formed in the 
presence of BP treatment. As with the current work, most 
of the previous methods suffer from the limitation of 
trying to assess a three-dimensional structure (the BMU) 
in two dimensions. This means that the area, width, and 
depth we report may not directly correspond to a volu­
metric measurement. One exception is where the remod­
eling site was reconstructed in three dimensions. That 
study found a signiﬁcant reduction in Rs.De with 
3 months of RIS treatment (-25%) although it is not clear 
whether these measures were restricted to those sites that 
were remodeled during treatment [3]. Our Rs.De results 
differ in that we did not show a signiﬁcant effect of BP 
treatment, although the magnitude of difference between 
control and treated animals was comparable (-15%). 
What the current work shows, however, is that signiﬁcant 
effects of BPs exist in other parameters, including Rs.Wi 
and, most importantly, the resorption cavity area, which 
previous methods have not assessed. On this basis, we 
suggest that the assessment of additional parameters such 
as Rs.Ar can provide important BMU-level information. 
Ultimately, the development of three-dimensional methods 
to assess the BMU are essential to advance our ability to 
study how alterations in its morphology occur with disease 
and treatment [14]. 
In conclusion, we show that reductions in resorption at 
the BMU level likely contribute to the mechanism through 
which BPs slow bone loss and that assessment of BMU-
level resorption is best done through comprehensive mea­
sures of Rs.Ar, Rs.Wi, and Rs.De. 
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